<DOC>
	<DOCNO>NCT01972893</DOCNO>
	<brief_summary>ZYD1 novel GLP-1 receptor agonist . The ZYD1 exhibit increase stability proteolytic cleavage , especially dipeptidyl peptidase-4 ( DPP-IV ) . ZYD1 potent antidiabetic agent without gastrointestinal side-effects . A first human ( FIH ) Phase I study intend evaluate safety , tolerability , pharmacokinetics pharmacodynamics ZYD1 normal healthy adult volunteer .</brief_summary>
	<brief_title>A Clinical Study Evaluate Safety , Tolerability , Pharmacokinetics ZYD1 , Following Subcutaneous Administration Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Age : 1845 year 2 . Mentally , physically , legally eligible give inform consent 3 . Male female volunteer weigh 5075 kg 4575 kg respectively 4 . Ability communicate effectively study personnel 5 . Willingness adhere protocol requirement 6 . For gender effect study , females history sterility least 1 year menopause use long acting nonhormonal contraceptive measure ( e.g. , intrauterine device ) recruit . 1 . Presence history hypersensitivity active inactive ingredient ZYD1 formulation 2 . Presence history pancreatitis time ( Serum Amylase/Serum Lipase upper normal limit ( UNL ) ) 3 . Presence history severe gastrointestinal disease last 6 month 4 . Presence history renal insufficiency time ( serum creatinine upper limit reference range ) 5 . Active liver disease and/or liver transaminases great 1.5 X UNL 6 . Subject personal family history medullary thyroid cancer 7 . Subject personal family history multiple endocrine neoplasia syndrome type 2 8 . Subject serum calcitonin &gt; 50 ng/L 9 . History presence systemic disorder disease ( e.g. , respiratory , gastrointestinal , endocrine , immunological , dermatological , neurological , psychiatric disease body system involvement ) 10 . Abnormal bleeding time ( BT ) , clot time ( CT ) , prothrombin time ( PT ) , activate partial prothrombin time ( APTT ) test day check 11 . History presence medication last 14 day include medication know interact Cytochrome P ( CYP ) 450 system 12 . History presence significant alcoholism drug abuse within past 1 year 13 . History presence significant smoking ( 10 cigarette per day ) consumption tobacco product ( 10 time per day ) 14 . Difficulty donate blood 15 . Systolic blood pressure 140 mmHg less 100 mmHg diastolic blood pressure 90 mmHg less 60 mmHg 16 . Pulse rate le 60/minute 100/minute 17 . Any clinically significant abnormal Xray laboratory finding screen 18 . History presence clinically significant electrocardiogram ( ECG ) abnormalities screen 19 . Major illness and/or major surgery last 3 month 20 . Volunteers participate drug research study present trial within past 3 month 21 . Volunteers donate one unit ( 350 ml ) blood past 3 month 22 . For gender effect study , female volunteer follow criterion recruit : History pregnancy lactation past 3 month Fertile female volunteer protect pregnancy adequate longterm antifertility device history less 1 year menopause Using hormonal contraceptive Using hormone replacement therapy Unable give assurance protection pregnancy 3 month participation trial Positive urine pregnancy test day checkin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Selective GLP-1 agonist</keyword>
</DOC>